VX15/2503 (USAN Council approved name "pepinemab") is a humanized monoclonal antibody that binds and blocks the signaling activity of SEMA4D. SEMA4D is an extracellular signaling molecule that regulates the migration of immune and inflammatory cells to sites of injury, cancer or infection. Pepinemab (VX15/2503)'s mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. We have shown in preclinical studies that the biological activities associated with an antibody blockade of SEMA4D can promote immune cell infiltration into tumors and the repair or prevention of neurological damage in neuroinflammatory and neurodegenerative diseases.
Note: Pepinemab (VX15/2503) is an investigational drug currently in clinical studies. It has not been demonstrated to be safe and effective for any disease indication. There is no guarantee that pepinemab (VX15/2503) will be approved for the treatment of any disease by the U.S. Food and Drug Administration or by any other health authority worldwide.
Vaccinex discovered and developed an immune-modulating, anti-semaphorin 4D (SEMA4D) antibody, pepinemab (VX15/2503) that was shown in preclinical studies to regulate the infiltration of immune cells into the tumor microenvironment, especially when combined with checkpoint inhibitor and other immunomodulatory therapies. Specifically, anti-SEMA4D induces an increase in tumor-specific cytotoxic T cells and a change in the balance of tumoricidal and regulatory macrophage toward a pro-inflammatory, anti-tumorigenic response.Learn more about Pepinemab (VX15/2503) for Immuno-Oncology
Huntington’s disease (HD) is a devastating neurodegenerative disease that results in uncontrolled movements and debilitating cognitive and behavioral changes. Astrocytes and microglia are key components of the brain that support neurons and shape neural networks by regulating formation and maintenance of synapses. Under conditions of physiological stress or injury, astrocytes and microglia transition from their normal function to an inflammatory state that can trigger or exacerbate degenerative processes in this and other neurological disorders. While it is widely believed that neuronal loss is irreversible, we believe other important elements that govern neurological activity, in particular glial cells and synapses, may be replenished or repaired with significant impact on disease progression. Vaccinex is investigating the ability of pepinemab (VX15/2503) to preserve normal glial cell function and to protect neurons from degeneration so as to modify the effects or delay the onset of this genetically determined disease by blocking the inflammatory response of astrocytes and microglia.
A Key Opinion Leader (KOL) Luncheon on Huntington's Disease (HD) was hosted by Vaccinex on February 6, 2018. The meetings featured presentations by Ira Shoulson, MD, (Georgetown University), Karl Kieburtz, MD, MPH (University of Rochester), and Maurice Zauderer, Ph.D. (Vaccinex, Inc.) who provided an update on the Company's SIGNAL trial (Phase 2 study of investigational pepinemab (VX15/2503) antibody in HD). Discussion included recent research and the current treatment landscape, as well as the unmet medical need for treating patients with Huntington's Disease.
To see and hear a replay of the KOL Luncheon, please click here to register or log in.Learn more about Pepinemab (VX15/2503) for Neurology
Vaccinex has developed an antibody discovery platform that enables efficient mammalian cell-based expression for expression of large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface envelope of a mammalian virus and the cell surface membrane of the infected cell. This allows us to combine the advantages of virus panning and cell sorting into one seamless selection process. This technology enables the rapid selection of 1010 antibody combinations and thus selection of high affinity leads with varied frameworks that recognize multiple epitopes. We believe selected antibodies are ideally suited for development because they have already passed mammalian cell quality control during the selection process.
We believe our ActivMAb technology offers: